

## Intervacc presents to the capital market on three occasions in March

**Intervacc AB (publ) is a Swedish biotechnology company developing breakthrough vaccines based on recombinant protein fusions. In March, the company will present at the DNB/Carnegie Healthcare Seminar, Stora Aktiedagarna and Stockholm Corporate Finance Life Science kapitalmarknadsdagar.**

*– At this time when more than 30,000 horses have been vaccinated with Strangvac<sup>®</sup>, several field studies have been completed and a long series of scientific articles have been published, it is time and of great importance to summarize and report on the company's current situation for the shareholders, says newly appointed CEO Carl-Johan Dalsgaard. In addition, there is a lot more going on, both in the short and long term, which I look forward to communicate.*

**Carl-Johan Dalsgaard will be presenting at:**

- » [Carnegie Healthcare Seminar](#), 9 March at 16:00.
- » [Stora Aktiedagarna 2026](#), 11 March at 16:25.
- » [Stockholm Corporate Finance Life Science kapitalmarknadsdagar](#), 17 March at 9:30.

**For more information please contact:**

Carl-Johan Dalsgaard, CEO  
Phone: +46 (0)8 120 10 600  
E-mail: [info@intervacc.se](mailto:info@intervacc.se)

*The information was submitted for publication, through the agency of the contact person set out above on March 9, 2026 at 08.30 CET.*

**About Strangvac**

Strangvac<sup>®</sup> is a vaccine against the severe equine disease called strangles. The vaccine is approved for sale and marketing in the EU as well as the UK, Iceland, Norway, and Liechtenstein and has been launched in Sweden, Denmark, Finland, the United Kingdom, France, Germany, Belgium, the Netherlands, Austria, Spain, Portugal, Ireland, Poland, Slovenia and Italy.

**About Intervacc**

Intervacc AB (publ) is an animal health group that develops vaccines for animals. The company's vaccines and vaccine candidates are based on many years of research at the Karolinska Institute and the Swedish University of Agricultural Sciences. The Intervacc share is listed on the Nasdaq First North Growth Market. For more information, see [intervacc.se](http://intervacc.se)

**Contact information for Certified Adviser**

Eminova Fondkommission AB  
E-mail: [adviser@eminova.se](mailto:adviser@eminova.se), Phone: +46 (0)8 – 684 211 10